



NSGO-CTU

Nordic Society of Gynaecological Oncology - Clinical Trial Unit

Agenda

NSGO-CTU Investigator Meeting

7th – 8th December 2023

Copenhagen, Denmark

Scandic Kødbyen Skelbækgade 3A

1717 Copenhagen V



Wednesday 6. December 2023

13:00-14:15 **NSGO-CTU Foundation Meeting** (Closed meeting)

Meeting Room 10 + 11

14:30-15:45 **NSGO Board Meeting** (Closed meeting)

Meeting Room 10 + 11

16:00-17:30 **NSGO-CTU Scientific Committee Meeting** (Closed meeting)

Meeting Room 10 + 11

18:00-19:00 **Dinner** (Closed Dinner for NSGO BOARD -, NSGO-CTU Foundation -, NSGO-CTU Scientific Committee Members and NSGO-CTU Office Staff)

Restaurant Mør

Thursday 7. December 2023

08:30-09:30 Registration & Exhibition

Foyer & Ballroom 3

09:30-09:50 Welcome by Medical Director

Future plans and status report of NSGO-CTU activities

Ballroom 1 + 2

[Mansoor Raza Mirza](#)

09:50-09:55 Cervical Cancer

Introduction to the Session

Ballroom 1 + 2

[Chairs: Maria Bjurberg and Kristine Madsen](#)

09:55-10:50 Cervical Cancer Trials

Ballroom 1 + 2

09:55-10:02 ENGOT-CX11/KEYNOTE-A18

A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer

[Domenica Lorusso](#)

10:02-10:09 ENGOT-CX10/BEATcc

A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix

[Ana Oaknin](#)

10:09-10:16 ENGOT-CX8/GCT1015-05

Randomized, open label, phase 1b/2 first line trial with Tisotumab Vedotin

Kristine Madsen

10:16-10:23 ENGOT-CX12/SGNTV003

A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Maria Bjurberg

10:23-10:30 ENGOT-CX19/eVOLVE

Randomized Phase 2/3 Trial of Volrustomig vs. placebo for patients with FIGO stage IIIC-IVA cervical cancer who have completed, and not progressed, following SOC CCRT (≥4 cycles)

Trine Jakobi Nøttrup

10:30-10:37 ENGOT-CX20

A Phase 3 Randomized, Active-Controlled, Open-Label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice as Second-Line or Third-Line Treatment for Patients with Recurrent or Metastatic Cervical Cancer

Kristina Lindemann

10:37-10:50 Discussion

Domenica Lorusso

Ana Oaknin

Trine Jakobi Nøttrup

Kristina Lindemann

10:50-11:15 Break & Exhibition

Ballroom 3

11:15-14:00 NSGO-CTU Scientific Satellite Symposium incl. Lunch
Endometrial Cancer Management in the Era of Immunotherapy

Ballroom 1 + 2 The Scientific Satellite Symposium is supported by an educational grant from GSK

Chairs: Line Bjørge and Henrik Roed

11:20-11:45 50 Years of Management of Endometrial Cancer
Jonathan Ledermann

11:45-12:10 Immunotherapy in Endometrial Cancer
Ana Oaknin

12:10-12:45 Management of Immune-related Toxicity
Domenica Lorusso

12:45-13:00 Discussion
Jonathan Ledermann
Ana Oaknin
Domenica Lorusso

13:00-14:00 Symposium Lunch

Restaurant Mør

14:00-14:05 Endometrial Cancer
Introduction to the Session

Ballroom 1 + 2

Chairs: Ane Gerda Zahl Eriksson and Gabriel Lindahl

14:05-15:10 Endometrial Cancer: Neoadjuvant, First - and Second Line Trials incl. Maintenance

Ballroom 1 + 2

14:05-14:12 PELENEO (Neoadjuvant study)
A phase II clinical trial investigating pembrolizumab and lenvatinib in

neoadjuvant treatment of advanced
endometrial cancer

[Kristina Lindemann](#)

14:12-14:19 ENGOT-EN11

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination with Adjuvant Chemotherapy with or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery with Curative Intent

[Trine Lembrecht Jørgensen](#)

14:19-14:26 ENGOT-EN6/RUBY part 1+2

A Phase 3 Randomized Open-Label Study of TSR-042, an anti-PD-1 Mono-clonal Antibody, Versus Investigator's Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer

[Gabriel Lindahl](#)

14:26-14:33 ENGOT-EN10/DUO-E

A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer

[Karin Grisan](#)

14:33-14:40 ENGOT-EN15/KEYNOTE-C93

A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting

[Heini Lassus](#)

14:40-14:47 ENGOT-EN24/DESTINY

An Open label, Randomized, Multicenter, Controlled, Phase III Study of First-Line Trastuzumab Deruxtecan (T-DXd) Monotherapy versus Carboplatin and Paclitaxel with or without Pembrolizumab in Patients with HER2-expressing (IHC 3+/IHC 2+) Mismatch Repair Proficient (pMMR) Primary Advanced or Recurrent Endometrial Cancer

[Mansoor Raza Mirza](#)

14:47-14:55 ENGOT-EN21

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects with *TP53WT* Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

[Kristiina Ojamaa](#)

14:55-15:02 ENGOT-EN23 (2nd line)

A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-Based Chemotherapy and Immunotherapy

[Ingvild Vistad](#)

15:02-15:25 Discussion

[Kristina Lindemann](#)

[Trine Lembrecht Jørgensen](#)

[Heini Lassus](#)

[Mansoor Raza Mirza](#)

[Kristiina Ojamaa](#)

[Ingvild Vistad](#)

[Katharina Bischof](#)

[Karin Grisan](#)

15:25-15:45 Break & Exhibition

Ballroom 3

17:00-20:30 NSGO-CTU Scientific Satellite Symposium incl. Dinner
Novel First Line Therapies in Ovarian Cancer

Ballroom 1 + 2 The Scientific Satellite Symposium is supported by an educational grant from AstraZeneca

Chairs: Hanna Dahlstrand and Mansoor Raza Mirza

**17:00-17:30 Bevacizumab and PARP-inhibitors
in Combination with
Immunotherapy:
Challenges/Missing Information in
Trial Design and Interpretation of
Results**

Nicoletta Colombo

**17:30-18:00 Current Maintenance Therapy
Approach in First Line Treatment**

Ingrid Boere

**18:00-18:30 The Role of Immunotherapy in
Ovarian Cancer**

Philipp Harter

18:30-19:00 Discussion

Nicoletta Colombo

Ingrid Boere

Philipp Harter

19:00-20:30 Symposium Dinner

Restaurant Mør

Please evaluate the day by scanning the QR code with
your mobile camera and open the link

Friday 8. December 2023

08:00-08:15 Ovarian Cancer: NSGO-CTU-HERO (Observational study)

Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study

Ballroom 1 + 2

Trine Jakobi Nøttrup

08:15-08:20 Ovarian Cancer: Surgical Trials

Introduction to the Session

Ballroom 1 + 2

Chairs: Trine Jakobi Nøttrup and Marta Lomnytska

08:20-08:40 Primary Surgery and HIPEC

Ballroom 1 + 2

08:20-08:27 OVHIPEC-2

Phase III randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

Berit Jul Mosgaard

08:27-08:40 Discussion

Berit Jul Mosgaard

Tine Henrichsen-Schnack

08:40-08:45 Ovarian Cancer: First Line Trials

Introduction to the Session

Ballroom 1 + 2

Chairs: Hanna Dahlstrand and Jørn Herrstedt

08:45-09:10 First Line Maintenance Therapy with Bevacizumab/PARP-i

Ballroom 1 + 2

08:45-08:52 ENGOT-OV25/PAOLA-1

Randomised, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced

FIGO Stage IIIB – IV High Grade Serous or Endometrioid Cancer, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance

[Gabriel Lindahl](#)

08:52-08:59 ENGOT-OV26/PRIMA

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

[Nicoline Raaschou-Jensen](#)

08:59-09:10 Discussion

[Gabriel Lindahl](#)

[Nicoline Raaschou-Jensen](#)

[Maarit Anttila](#)

09:10-09:55 Immunotherapy as First Line Treatment

Introduction to the Session

Ballroom 1 + 2

Chairs: [Hanna Dahlstrand](#) and [Jørn Herrstedt](#)

09:10-09:17 ENGOT-OV44/FIRST

An adaptive Randomized Phase III Comparison of Standard Platinum Based Treatment Versus Platinum and TSR-042 followed by Niraparib and TSR-042 maintenance Therapy in Patients with epithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum

[Jørn Herrstedt](#)

09:17-09:24 ENGOT-OV46/DUO-0

Phase III Randomized, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients

Henna Kärkkäinen

09:24-09:33 ENGOT-OV45/ATHENA

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

Josefin Fernebro

09:33-09:55 Discussion

Henna Kärkkäinen

Josefin Fernebro

09:55-10:30 Break & Exhibition

Ballroom 3

10:30-11:10 Ovarian Cancer: Platinum is an Option & Maintenance

Introduction to the Session

Ballroom 1 + 2

Chairs: Trine Zeeberg Iversen and Birute Brasiuniene

10:30-10:46 ENGOT-OV56/DOVACC

A Randomized Clinical Trial Investigating Olaparib, Durvalumab and UV1 as Maintenance Therapy in BRCAwt Patients with Relapsed Ovarian Cancer

Susanne Malander

10:46-10:53 KANDOVA

A two-part Phase Ib/IIa study to evaluate the safety and tolerability of KAND567 in combination with carboplatin therapy and to determine the Recommended Phase II Dose (RPIID). An open-label, multicenter dose escalation study with an expansion cohort in women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

Hanna Dahlstrand

10:53-11:10 Discussion

[Susanne Malander](#)

[Hanna Dahlstrand](#)

[Maria Dimoula](#)

[Trine Stokstad](#)

11:10-12:00 Ovarian Cancer: Platinum is Not an Option and Palliation

Introduction to the Session

Ballroom 1 + 2

Chairs: [Kristina Lindemann](#) and [Susanne Malander](#)

11:10-11:17 ENGOT-OV65

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

[Anne Marie Hansson](#)

11:17-11:24 ENGOT-OV68/ARTISTRY-7

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

[Birute Brasiuniene](#)

11:24-11:31 ENGOT-OV79/REFRaME-01

A randomized phase 2/3 Study of Luvelta vs. Standard Chemotherapy in Platinum Resistant Ovarian Cancer

[Trine Zeeberg Iversen](#)

11:31-11:38 EPIK-O

A phase III, multi-center, randomized (1:1), openlabel, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single

agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

[Annika Auranen](#)

11:38-11:45 PEACE

Palliation in gynae-oncology: Evaluation and Assessment of satisfaction with care

[Kristina Lindemann](#)

11:45-12:00 Discussion

[Anne Marie Hansson](#)

[Birute Brasiuniene](#)

[Trine Zeeberg Iversen](#)

[Annika Auranen](#)

[Ulrika Joneborg](#)

12:00-13:00 Lunch

Restaurant Mør

13:00-13.15 Coffee & Exhibition

Ballroom 3

13:15-15:10 Translational Research Session

Introduction to the Session

Ballroom 1 + 2

Chair: [Line Bjørge](#)

13:20-13:45 The untapped potential of ascites derived ctDNA to direct precision medicine in ovarian cancer

[Caroline Ford](#)

13:45-13:55 Analysis of the impact of germline and somatic alterations, PD-L1

**expression and chemotherapy
modifications on the outcomes of
advanced ovarian cancer patients**

[Rasa Malonyté](#)

**13:55-14:25 Establishment and use of high-grade
serous ovarian cancer organoids for
translational research**

[Krister Wennerberg](#)

**14:25-14:50 Single-cell profiling of low-stage
endometrial cancers identifies low
epithelial vimentin expression as a
marker of recurrent disease**

[Hilde Eide Lien](#)

14:50-15:10 Discussion

[Caroline Ford](#)

[Rasa Malonyté](#)

[Krister Wennerberg](#)

[Hilde Eide Lien](#)


15:10-15:15 Closing Remarks

[Line Bjørge](#)


Ballroom 1 + 2

Please evaluate the day and the meeting in general by scanning the below QR codes with your mobile camera and open the link

Thursday:



Friday:



General:



This Meeting is Sponsored by

Gold Sponsors:



Exhibitors:



Other Sponsors:

